Regional distribution of serotonergic pre‐ and postsynaptic markers in human brain

Presynaptic markers Paroxetine is a new antidepressant which is a selective serotonin (5-HT) uptake blocker. [3Hl-paroxetine binding sites have been described in human platelets (1) and rat cortex (2 ) , and are closely related to the 5-HT uptake sites. 13Hl-paroxetine is a more selective ligand for labelling of 5-HT uptake sites than [3Hl-imipramine (3). In rat brain, selective destruction of 5-HT nerve terminals with 5,7-dihydroxytryptamine (5,7-DHT) leads to a 94% reduction in 5-HT levels and a 90% reduction in 13H1-paroxetine binding (2 ) , but to only a 42% reduction in [3Hl-imipramine binding (4). Therefore, we investigated the binding characteristics of [3Hl-paroxetine in human brain to determine its use as a specific 5-HT presynaptic marker.

[1]  Y. Agid,et al.  Distribution of Specific High‐Affinity Binding Sites for [3H]Imipramine in Human Brain , 1981, Journal of neurochemistry.

[2]  M. Hamon,et al.  [3H]8‐Hydroxy‐2‐(Di‐n‐Propylamino)Tetralin Binding to Pre‐ and Postsynaptic 5‐Hydroxytryptamine Sites in Various Regions of the Rat Brain , 1985, Journal of neurochemistry.

[3]  Marc Laruelle,et al.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites , 1988, Biological Psychiatry.

[4]  J. Leysen,et al.  [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. , 1982, Molecular pharmacology.

[5]  P. Plenge,et al.  High affinity binding of [3H]paroxetine and [3H]imipramine to human platelet membranes. , 1983, European journal of pharmacology.

[6]  Y. Agid,et al.  [3H]imipramine binding in subcellular fractions of rat cerebral cortex after chemical lesion of serotonergic neurons. , 1983, European journal of pharmacology.

[7]  S. Z. Langer,et al.  Solubilization and characterization of the 5-hydroxytryptamine transporter complex from rat cerebral cortical membranes. , 1986, European journal of pharmacology.

[8]  S. Snyder,et al.  Two distinct central serotonin receptors with different physiological functions. , 1981, Science.

[9]  P. Davies,et al.  REGIONAL DISTRIBUTION OF MONOAMINES AND THEIR METABOLITES IN THE HUMAN BRAIN , 1978, Journal of neurochemistry.

[10]  J. Leysen,et al.  Role and localization of serotonin2 (S2)-receptor-binding sites: effects of neuronal lesions. , 1983, Advances in biochemical psychopharmacology.

[11]  P. Plenge,et al.  High affinity binding of3H-paroxetine and3H-imipramine to rat neuronal membranes , 2006, Psychopharmacology.

[12]  S. Peroutka,et al.  Pharmacological Differentiation and Characterization of 5‐HT1A, 5‐HT1B, and 5‐HT1C Binding Sites in Rat Frontal Cortex , 1986, Journal of neurochemistry.

[13]  J. Hyttel,et al.  Citalopram — Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity , 1982, Progress in Neuro-Psychopharmacology and Biological Psychiatry.